How to Get Zetia (Ezetimibe) in South Carolina

What Is Ezetimibe and Why South Carolina Patients Use It

Ezetimibe is a cholesterol-absorption inhibitor that blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, reducing dietary and biliary cholesterol absorption by roughly 50 percent [1]. South Carolina has one of the higher rates of cardiovascular disease mortality in the southeastern United States, making LDL-lowering therapy a frequent clinical priority for primary care providers across the state [2].

The drug is approved by the FDA as an adjunct to diet and exercise for primary hyperlipidemia, mixed hyperlipidemia, homozygous familial hypercholesterolemia (HoFH), and homozygous sitosterolemia [3]. Ezetimibe 10 mg once daily reduces LDL cholesterol by approximately 18 to 20 percent as monotherapy and by an additional 21 to 27 percent when added to a statin [4].

The landmark IMPROVE-IT trial (N=18,144) established that adding ezetimibe to simvastatin 40 mg reduced the composite cardiovascular endpoint (cardiovascular death, major coronary events, or noncardiac stroke) by an absolute 2.0 percentage points over seven years (32.7% vs. 34.7%, hazard ratio 0.936, P<0.001) compared with simvastatin alone [5]. This was the first large-scale trial to show that non-statin LDL lowering translates into fewer heart attacks and strokes, not merely a number on a lab report.

The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol states: "In patients with clinical ASCVD, if LDL-C remains ≥70 mg/dL on maximally tolerated statin therapy, it is reasonable to add ezetimibe" [6]. South Carolina cardiologists and internists rely on this language when writing prescriptions or submitting prior authorization requests.

South Carolina Prescribing Laws: Who Can Write the Prescription

Any physician (MD or DO), nurse practitioner (NP), or physician assistant (PA) holding an active South Carolina license may prescribe ezetimibe. South Carolina nurse practitioners operate under collaborative practice agreements for certain controlled substances, but ezetimibe is not a controlled substance. NPs with full prescriptive authority may write the prescription independently [7].

Telehealth prescribing is explicitly permitted under the South Carolina Telehealth Alliance framework and the South Carolina Telehealth Act (S.C. Code Ann. Section 40-47-37). A prescriber must establish a valid patient-provider relationship, which in South Carolina may be formed via a synchronous audio-video encounter. Text-only or asynchronous questionnaire-only encounters do not satisfy the state's standard-of-care requirement for a new prescription in most clinical situations.

Pharmacists in South Carolina cannot initiate a new ezetimibe prescription, but they can perform collaborative drug therapy management (CDTM) under a written protocol with a supervising physician.

Lab Work Required Before Starting Zetia in South Carolina

A fasting lipid panel is the minimum laboratory requirement before a licensed South Carolina provider will issue an ezetimibe prescription [8]. Most providers also request:

• Fasting lipid panel (total cholesterol, LDL, HDL, triglycerides)
• Comprehensive metabolic panel (CMP) to screen for hepatic impairment
• HbA1c or fasting glucose if the patient has metabolic risk factors
• Thyroid-stimulating hormone (TSH) if secondary dyslipidemia is suspected

Liver function tests are not required by the FDA label for ezetimibe initiation the way they are for statins, because ezetimibe's hepatic metabolism differs significantly from HMG-CoA reductase inhibitors [3]. However, most South Carolina providers obtain a CMP at baseline to document liver health before adding any lipid-lowering agent to a statin.

Repeat lipid panels are typically ordered four to twelve weeks after starting ezetimibe to assess treatment response, consistent with ACC/AHA guideline monitoring intervals [6]. Quest Diagnostics and LabCorp both operate dozens of patient service centers across South Carolina, and most major hospital systems (MUSC, Prisma Health, Atrium Health) offer same-day phlebotomy.

How to Get Zetia Through Telehealth in South Carolina

South Carolina residents do not need to leave home to obtain an ezetimibe prescription. A telehealth visit through a South Carolina-licensed provider follows this sequence:

1. Schedule a synchronous video visit. The provider must be licensed in South Carolina. Confirm this before booking.
2. Upload or share recent lab results. A lipid panel drawn within the past six to twelve months is usually acceptable for an initial telehealth prescription. Older results may require a new draw before the provider prescribes.
3. Complete the medical history intake. Disclose all current medications, particularly statins, fibrates, bile-acid sequestrants, and any anticoagulants such as warfarin, because ezetimibe modestly increases cyclosporine exposure and bile-acid sequestrants may reduce ezetimibe absorption by roughly 55 percent when co-administered [3].
4. Attend the video visit. The provider reviews labs, confirms the indication, discusses goals, and issues the prescription electronically.
5. Choose a pharmacy. The provider sends the e-prescription to a South Carolina retail pharmacy, a national mail-order pharmacy, or a 503A compounding pharmacy licensed in the state.

HealthRX connects South Carolina patients with board-certified clinicians available for same-day or next-day video appointments. After the visit, most patients receive their prescription confirmation within two hours.

The table below summarizes timing expectations for South Carolina patients using different prescription-fulfillment routes:

| Route | Time to First Dose | |---|---| | Local retail pharmacy (CVS, Walgreens, Walmart, Publix) | Same day to 24 hours after e-prescription | | Mail-order pharmacy (Express Scripts, Optum Rx) | 3 to 5 business days | | 503A compounding pharmacy (SC-licensed) | 5 to 10 business days | | In-person physician visit + local pharmacy | 1 to 3 days total |

Generic Ezetimibe vs. Brand-Name Zetia in South Carolina

The FDA approved the first generic ezetimibe in December 2012 [3]. As of 2025, multiple manufacturers produce AB-rated generic ezetimibe 10 mg tablets. The generic is therapeutically equivalent to brand-name Zetia and is dispensed interchangeably unless the prescriber writes "dispense as written" (DAW) on the prescription [9].

Cash prices at South Carolina pharmacies vary by location and discount program. GoodRx and similar programs list generic ezetimibe 10 mg, 30 tablets, at $15 to $28 at chains including Walmart, Costco, and Kroger pharmacies throughout the state. Brand-name Zetia without insurance can exceed $300 for a 30-day supply, making the generic the default choice for most uninsured or underinsured South Carolina patients [10].

Merck's patient assistance program (Merck Helps) may cover brand-name Zetia for eligible low-income patients, but applicants must meet income thresholds and submit documentation through the program website. For most South Carolina patients, generic ezetimibe provides identical clinical outcomes at a fraction of the cost.

Insurance Coverage and Prior Authorization in South Carolina

Commercial Insurance

Most commercial health plans sold on the South Carolina ACA marketplace and employer-sponsored plans cover generic ezetimibe on Tier 2 or Tier 3 of their formulary. Prior authorization (PA) is common. Insurers typically require documentation that the patient:

• Has a confirmed diagnosis of hyperlipidemia or ASCVD (ICD-10: E78.00 to E78.5, or I25.10)
• Has tried and failed, or has a documented contraindication to, maximally tolerated statin therapy
• Has a current lipid panel showing LDL above the plan's threshold (often 70 mg/dL for high-risk patients or 100 mg/dL for moderate-risk patients)

The ACC/AHA guideline language cited above is routinely used by South Carolina providers in PA letters [6]. Approval timelines range from 24 hours for urgent PA requests to 14 days for standard review, per South Carolina Department of Insurance regulations.

South Carolina Medicaid (Healthy Connections)

Ezetimibe is not covered under the South Carolina Medicaid Healthy Connections fee-for-service formulary as of 2025 [11]. Medicaid managed care organizations operating in South Carolina may have different formularies; patients should call the member services number on their Healthy Connections card to verify coverage. For uninsured or Medicaid patients, generic ezetimibe at $15 to $28 cash price is usually the most accessible option.

Medicare Part D

Medicare Part D plans vary. The Medicare formulary finder at medicare.gov allows South Carolina beneficiaries to search their specific plan. Ezetimibe appears on most Part D formularies at Tier 2 or Tier 3, with copays ranging from $5 to $47 per month depending on the plan.

Transferring an Out-of-State Zetia Prescription to South Carolina

Patients relocating to South Carolina or spending extended periods in the state can transfer an existing ezetimibe prescription. South Carolina pharmacy law permits pharmacist-to-pharmacist transfers for non-controlled substances, including ezetimibe, provided:

• The original prescription has remaining refills authorized by the out-of-state prescriber
• The receiving South Carolina pharmacy contacts the originating pharmacy directly
• The patient presents valid identification

If no refills remain, or if the original prescriber is not licensed to practice in South Carolina, the patient will need a new prescription from a South Carolina-licensed provider. A telehealth visit is the fastest path in this situation, typically requiring only updated labs and a 20- to 30-minute video consultation.

Electronic prescriptions sent from out-of-state providers to South Carolina pharmacies are valid only if the prescriber holds active South Carolina licensure or meets interstate prescribing criteria under the Interstate Medical Licensure Compact (IMLC) or the Nurse Licensure Compact (NLC) [12].

Ezetimibe and Combination Therapy: What South Carolina Providers Prescribe Most

Ezetimibe is most commonly prescribed in South Carolina alongside a moderate- or high-intensity statin. The SHARP trial (N=9,270) demonstrated that simvastatin 20 mg plus ezetimibe 10 mg reduced major atherosclerotic events by 17 percent (relative risk 0.83 to 95% CI 0.74 to 0.94, P<0.001) in patients with chronic kidney disease, a population with high prevalence in South Carolina given the state's rates of diabetes and hypertension [13].

Fixed-dose combination tablets containing ezetimibe are also available:

• Vytorin (ezetimibe 10 mg / simvastatin 10, 20, 40, or 80 mg): FDA-approved; note that the 80 mg simvastatin dose carries an FDA myopathy warning [3]
• Liptruzet (ezetimibe 10 mg / atorvastatin 10, 20, 40, or 80 mg): FDA-approved and preferred by some South Carolina cardiologists for its stronger LDL-lowering effect

A 2020 meta-analysis in the Journal of the American College of Cardiology (N=176,000 patient-years across 15 trials) confirmed that each 1 mmol/L (39 mg/dL) reduction in LDL cholesterol lowers major vascular events by 22 percent regardless of the mechanism used, supporting ezetimibe's place as an additive agent [14].

For patients who cannot tolerate any statin, ezetimibe monotherapy remains a reasonable second-line option. The 2019 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction notes that ezetimibe monotherapy is appropriate when statin intolerance is confirmed after a structured statin challenge [15].

Side Effects South Carolina Patients Should Discuss With Their Provider

Ezetimibe's adverse effect profile is favorable. The most common side effects reported in clinical trials at rates above placebo include upper respiratory infection (4.3% vs. 2.5% placebo), diarrhea (4.1% vs. 3.7%), arthralgia (3.0% vs. 2.2%), and sinusitis (2.8% vs. 2.2%) [3].

Myopathy risk is low with ezetimibe monotherapy. In combination with statins, myopathy risk increases marginally, consistent with the statin component rather than ezetimibe itself [5]. Patients in South Carolina who experience unexplained muscle pain, tenderness, or weakness on combination therapy should have creatine kinase (CK) measured promptly [6].

Hepatic effects deserve attention when ezetimibe is combined with statins. The FDA label notes that consecutive elevations in liver transaminases greater than three times the upper limit of normal occurred in 1.3% of patients on ezetimibe plus simvastatin vs. 0.4% on simvastatin alone in clinical trials [3]. Annual or semi-annual CMP monitoring is standard practice among South Carolina internists prescribing combination therapy.

Pregnancy category considerations: ezetimibe is contraindicated in pregnancy. The FDA label advises discontinuation when pregnancy is detected [3]. South Carolina providers prescribing to women of childbearing age should document contraceptive counseling.

Dosing and Administration for South Carolina Patients

The standard adult dose is ezetimibe 10 mg once daily. There is no dose titration schedule; 10 mg is both the starting and the maximum approved dose [3]. The tablet may be taken with or without food, at any time of day, making adherence relatively simple.

Timing relative to bile-acid sequestrants matters. Cholestyramine and colesevelam reduce ezetimibe's area under the curve (AUC) by approximately 55 percent [3]. South Carolina providers who co-prescribe both agents should instruct patients to take ezetimibe at least two hours before or four hours after the bile-acid sequestrant.

No dose adjustment is required in mild hepatic impairment (Child-Pugh score 5 to 6). Ezetimibe is not recommended in moderate or severe hepatic impairment (Child-Pugh score greater than 6) [3]. Renal impairment does not require dose adjustment.

503A Compounding Pharmacies in South Carolina

South Carolina-licensed 503A pharmacies may prepare ezetimibe compounded formulations for patients with documented medical needs, such as difficulty swallowing tablets or confirmed excipient allergies. Section 503A of the Federal Food, Drug, and Cosmetic Act governs these pharmacies, and they must operate under a valid prescription from a licensed South Carolina provider [16].

Compounded ezetimibe is not FDA-approved and should not be used interchangeably with FDA-approved generic tablets absent a specific clinical justification. The South Carolina Board of Pharmacy maintains a public list of licensed compounding pharmacies at llr.sc.gov/pharmacy. Patients should verify that any 503A pharmacy filling a South Carolina prescription holds an active state license before accepting a compounded preparation.

Monitoring After Starting Ezetimibe in South Carolina

After starting ezetimibe, South Carolina providers typically follow this schedule:

• 4 to 12 weeks post-initiation: Repeat fasting lipid panel to confirm LDL response [6]
• 3 to 6 months: Repeat CMP if on combination statin therapy
• Annually: Lipid panel, CMP, and assessment of adherence and cardiovascular risk [8]

If LDL remains above goal despite maximally tolerated statin plus ezetimibe, South Carolina providers may consider adding a PCSK9 inhibitor (alirocumab or evolocumab). The FOURIER trial (N=27,564) showed evolocumab reduced LDL by 59 percent (from a median of 92 mg/dL to 30 mg/dL) and reduced major adverse cardiovascular events by 15 percent (hazard ratio 0.85, P<0.001) when added to statin therapy [17]. Prior authorization for PCSK9 inhibitors in South Carolina almost always requires documented ezetimibe trial and failure first.

Getting Started: Practical Steps for South Carolina Residents

South Carolina residents ready to start ezetimibe should follow these concrete steps:

1. Gather lab results. A fasting lipid panel drawn within the past six months is ideal. If you do not have recent results, order labs through your insurer's network or a cash-pay lab (LabCorp, Quest) before or immediately after your telehealth appointment.
2. Book a South Carolina-licensed telehealth provider. Confirm the provider holds an active SC license before scheduling.
3. Prepare a medication list. Include all supplements, especially red yeast rice products, which contain naturally occurring lovastatin and interact with ezetimibe's statin combinations.
4. Request a 90-day supply. Many South Carolina pharmacies and all major mail-order pharmacies dispense 90-day supplies, reducing cost-per-tablet and improving adherence.
5. Check your formulary. Use your insurance card's member portal or call the number on the back of the card to confirm coverage and copay before the prescription is sent.

Patients on South Carolina Medicaid who are denied coverage should ask their provider to document medical necessity and request an exception review, or pay the cash price of $15 to $28 for generic ezetimibe.